Expanding the boundaries of clinical practice: building on experience with targeted therapiesFIZAZI, K.Annals of oncology. 2009, Vol 20, issn 0923-7534, 32 p., SUP1Conference Proceedings

Dose-intensité de la chimiothérapie dans les cancers bronchiques à petites cellules = Dose-intensity of chemotherapy in small-cell lung cancerLE CESNE, A; FIZAZI, K.Cancérologie aujourd'hui (Paris). 1999, Vol 8, Num 2, pp 103-109, issn 1140-9916Article

How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agentsRAVAUD, A.Annals of oncology. 2009, Vol 20, issn 0923-7534, i7-i12, SUP1Conference Paper

Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancerSCAGLIOTTI, G. V.Annals of oncology. 2007, Vol 18, issn 0923-7534, x32-x41, SUP10Conference Paper

Autogreffe dans les cancers du testicule : Greffes et Cancer = Autografts in testicular cancerMASSARD, C; FIZAZI, K.Oncologie (Paris). 2007, Vol 9, Num 12, pp 821-826, issn 1292-3818, 6 p.Article

Avancées dans l'ostéolyse maligne = Advances in malignant osteolysisFIZAZI, K.La Lettre du cancérologue (Boulogne). 2002, Vol 11, Num 6, pp 23-25, issn 1165-113X, 3 p., SUPArticle

Carcinome épidermoïde de la verge : Indications thérapeutiques et résultats = Squamous cell carcinoma of the penis : treatment indications and resultsSORIA, J.-C; FIZAZI, K.Cancérologie aujourd'hui (Paris). 1997, Vol 6, Num 3, pp 136-145, issn 1140-9916Article

Chimiothérapie des CAPI : quelles leçons peut-on en tirer en 2008 ? : Les dossiers d'Oncologie : Les carcinomes de primitif inconnu (CAPI) = CUP and chemotherapy : what have we learnt?MASSARD, C; FIZAZI, K.Oncologie (Paris). 2008, Vol 10, Num 12, pp 728-732, issn 1292-3818, 5 p.Article

A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activitiesCHRISTENSEN, J. G.Annals of oncology. 2007, Vol 18, issn 0923-7534, x3-x10, SUP10Conference Paper

Is one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasmsFIZAZI, K; ZELEK, L.Annals of oncology. 2000, Vol 11, Num 2, pp 133-149, issn 0923-7534Article

Advances in the treatment of gastrointestinal stromal tumoursJUDSON, I; DEMETRI, G.Annals of oncology. 2007, Vol 18, issn 0923-7534, x20-x24, SUP10Conference Paper

Surrogate biomarkers in evaluating response to anti-angiogenic agents : focus on sunitinibDEPRIMO, S. E; BELLO, C.Annals of oncology. 2007, Vol 18, issn 0923-7534, x11-x19, SUP10Conference Paper

Les tumeurs germinales de stade métastatique : Les tumeurs des organes génitaux externes de l'homme = Metastatic Germ Cell Tumours : Tumours of the Male External GenitaliaMASSARD, C; LORIOT, Y; FIZAZI, K et al.Oncologie (Paris). 2014, Vol 16, Num 4, pp 161-165, issn 1292-3818, 5 p.Article

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)LORIOT, Y; BIANCHINI, D; MASSARD, C et al.Annals of oncology. 2013, Vol 24, Num 7, pp 1807-1812, issn 0923-7534, 6 p.Article

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumorsMASSARD, C; KRAMAR, A; BEYER, J et al.Annals of oncology. 2013, Vol 24, Num 2, pp 322-328, issn 0923-7534, 7 p.Article

Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upSCHMOLL, H.-J; JORDAN, K; HUDDART, R et al.Annals of oncology. 2010, Vol 21, issn 0923-7534, v140-v146, SUP5Article

Toxicity symptom reporting by patients and clinicians during phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naìve metastatic prostate cancer (GETUG-AFU 15/0403)GRAVIS, G; FIZAZI, K; ESTERNI, B et al.2010 ASCO Annual Meeting. 2010, 1Conference Paper

Non-germ cell tumours arising in germ cell tumours (teratoma with malignant transformation) in men : CT and MR findings : Imaging Soft Tissue SarcomasATHANASIOU, A; VANEL, D; EL MESBAHI, O et al.European journal of radiology. 2009, Vol 69, Num 2, pp 230-235, issn 0720-048X, 6 p.Article

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors : a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)CULINE, S; KERBRAT, P; BIRON, P et al.Annals of oncology. 2007, Vol 18, Num 5, pp 917-924, issn 0923-7534, 8 p.Article

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumoursFIZAZI, K; PROW, D. M; PAGLIARO, L. C et al.British journal of cancer. 2002, Vol 86, Num 10, pp 1555-1560, issn 0007-0920Article

Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumoursFIZAZI, K; FARHAT, F; THEODORE, C et al.British journal of cancer. 1997, Vol 75, Num 1, pp 76-78, issn 0007-0920Article

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancerBEYER, J; ALBERS, P; COHN-CEDERMARK, G et al.Annals of oncology. 2013, Vol 24, Num 4, pp 878-888, issn 0923-7534, 11 p.Article

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trialGROSS-GOUPIL, M; FOURCADE, A; KAMINSKY, M. C et al.European journal of cancer (1990). 2012, Vol 48, Num 5, pp 721-727, issn 0959-8049, 7 p.Article

Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT) : results of the sCR2 international studyFIZAZI, K; OLDENBURG, J; TJULANDIN, S et al.Annals of oncology. 2008, Vol 19, Num 2, pp 259-264, issn 0923-7534, 6 p.Article

Page / 3